Cancer diagnostics firm Neoprobe (NYSE Amex:NEOP) has filed a regulatory document that gives it the right to sell up to $100 million in shares. However, the Dublin, Ohio-based company has no immediate plans to issue those new shares, CFO Brent Larson said. “This is just good corporate governance,” Larson said. “There are no plans to […]
Cancer diagnostics company Neoprobe (NYSE Amex:NEOP) has avoided a proxy fight with its largest shareholder by coming to an agreement with Platinum Montaur Life Sciences on board nominations. Platinum last month had threatened Neoprobe with a proxy fight aimed at installing three new directors on the Dublin, Ohio-based company’s board. Now, with Neoprobe agreeing to […]
Incorporating aquatic therapy can enhance patient outcomes and shorten recovery times for health care professionals. In the Chicago suburbs, the demand for such programs is rising.
The newly installed CEO of cancer diagnostics firm Neoprobe (NYSE Amex:NEOP) said the company is again delaying its FDA application to commercialize its radiopharmaceutical Lymphoseek. As recently as earlier this month, the company said it expected in the second quarter to file with the U.S. Food and Drug Administration a New Drug Application (NDA) for […]
As cancer diagnostics firm Neoprobe (NYSE Amex: NEOP) marches toward FDA approval of its “game-changing” radiopharmaceutical Lymphoseek and its share price continues to climb, many of the company’s shareholders are likely wondering when they’ll get the chance to cash out. There’s certainly plenty of investor interest in the company. Neoprobe’s shares are up a whopping […]
Neoprobe‘s (NYSE Amex:NEOP) largest shareholder said it’s considering launching a proxy fight aimed at installing three new directors on the cancer diagnostics company’s board. Platinum-Montaur Life Sciences said in a regulatory filing that it is nominating three candidates for Dublin, Ohio-based Neoprobe’s board and that it “reserve[s] the right to solicit proxies to see that […]
Cancer diagnostics firm Neoprobe (NYSE Amex:NEOP) plans to file for U.S. regulatory approval of its cancer-tracing agent Lymphoseek next quarter. CEO David Bupp confirmed on a conference call with investors that the Dublin, Ohio company during the second quarter would file a New Drug Application (NDA) for the tracing agent with the U.S. Food and […]
Across the nation, state-based health insurance exchanges are searching for ways to better serve their communities while making enrollment easier, more personal, and more accessible for everyone.
Shares of Neoprobe (NYSE Amex:NEOP) continue their strong performance of recent weeks, rising by as much as 8 percent in early Friday trading after the company published results from a phase 2 clinical trial of its cancer-targeting agent.
Neoprobe (NYSE Amex:NEOP) has reached an agreement to license imaging technology from Naviscan. The combined technology could produce images that allow surgeons to more precisely target cancerous lymph nodes for removal.
It was a strange day on Wall Street for Neoprobe (AMEX: NEOP) as the company's shares hit a 52-week high while also ending the day down about 3 percent. The early surge may have been related to the company's continued progress on its drug Lymphoseek, a tracing agent that identifies cancerous lymph nodes in patients with breast cancer and melanoma.
Neoprobe Corp. (OTCBB:NEOP) has received approval for its common stock to be listed on the NYSE Amex.
Employee assistance programs have become essential tools for organizations aiming to address mental health challenges, reduce burnout and foster healthier workplaces.
Neoprobe Corp. (OTCBB:NEOP) continues to take steps down the regulatory path aimed at restarting development efforts for its RIGScan cancer-detecting technology.
Neoprobe Corp. (OTCBB:NEOP) has hired a biotechnology and pharmaceuticals industry veteran as its chief development officer. Mark Pykett, 46, steps into the role, which calls for him to assist the company with its product and business development, partnering and investor relations efforts.
Neoprobe Corp.'s (OTCBB:NEOP) third-quarter loss narrowed, but more importantly, the company remains on track to file for regulatory approval of its cancer-detecting drug Lymphoseek early next year.
Neoprobe Corp. (OTCBB:NEOP) has raised $6 million by selling 3.2 million shares of its common stock to unidentified institutional investors.
Neoprobe Corp. (OTCBB:NEOP) has taken a step forward in the often-lengthy regulation process as it lays plans to commercialize its cancer-detection drug, RIGScan.